Valuation: AIT Therapeutics Inc

Market Cap 6.13M 5.37M 4.95M 4.63M 8.71M 579M 8.91M 59.62M 23.02M 286M 23.02M 22.51M 993M P/E 2025
-0.4x
P/E 2026 -0.17x
Enterprise Value 17.87M 15.65M 14.45M 13.49M 25.4M 1.69B 25.97M 174M 67.11M 834M 67.12M 65.65M 2.89B EV / Sales 2025
7.78x
EV / Sales 2026 2.48x
Free-Float
84.86%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 61 27/03/2026
Director of Finance/CFO 53 05/01/2026
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 58 10/08/2017
Director/Board Member 54 02/01/2018
Director/Board Member 65 13/08/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.13M
-1.50%+5.56%-31.01%-13.89% 161B
-0.06%+2.09%-5.92%-6.73% 104B
-1.57%+3.82%-5.93%+47.83% 54.8B
+0.56%-2.02%+51.27%+51.98% 53.31B
-0.47%+10.29%-9.17%-40.43% 42.76B
+1.90%+14.12% - - 33.49B
-0.23%+1.32%-18.94%-45.30% 27B
+1.09%+7.57%+62.05%-6.01% 25.06B
-1.13%+6.41%-10.70%-3.51% 20.78B
Average -0.14%+5.30%+3.96%-2.01% 58.03B
Weighted average by Cap. -0.50%+4.65%-5.70%-1.48%

Financials

2025 2026
Net sales 3.7M 3.24M 2.99M 2.8M 5.26M 350M 5.38M 36.04M 13.91M 173M 13.91M 13.61M 600M 7.68M 6.72M 6.21M 5.8M 10.91M 726M 11.16M 74.7M 28.84M 358M 28.84M 28.2M 1.24B
Net income -46.62M -40.82M -37.69M -35.19M -66.25M -4.41B -67.76M -454M -175M -2.17B -175M -171M -7.55B -33.25M -29.11M -26.88M -25.1M -47.24M -3.14B -48.32M -323M -125M -1.55B -125M -122M -5.38B
Net Debt 4.77M 4.18M 3.86M 3.6M 6.78M 451M 6.93M 46.41M 17.92M 223M 17.92M 17.52M 773M 11.74M 10.28M 9.49M 8.86M 16.69M 1.11B 17.07M 114M 44.1M 548M 44.1M 43.13M 1.9B
Logo AIT Therapeutics Inc
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Employees
-